A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder

Clinical Neuropharmacology · Published 2026-06-15 · DOI 10.1097/wnf.0000000000000693

Authors (5)

Jon E. Grant, Sophie Boutouis, Laurie Avila, Megha Neelapu, Dustin Ehsan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Grant, J., Boutouis, S., Avila, L., et al. (2026). A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000693

Related articles

• Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study · Clinical Neuropharmacology · 2026 · Same journal
• Viceroys in the Garden With the Monarch Butterflies: Medical Mimics of Catatonia · Clinical Neuropharmacology · 2025 · Same journal
• Impact of Levetiracetam Cost on Epilepsy in a Resource-limited Country · Clinical Neuropharmacology · 2025 · Same journal
• Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review · Clinical Neuropharmacology · 2025 · Same journal
• Amantadine Reduces Adverse Cardiovascular Outcomes in Patients With Parkinsonism or Parkinson Disease: A Global Propensity Score Matched Analysis · Clinical Neuropharmacology · 2025 · Same journal
• A Case of Post–Acute Severe Acute Respiratory Syndrome Coronavirus 2–Induced Focal Nonconvulsive Status Epilepticus With Impairment of Consciousness Initially Diagnosed as Anxiety · Clinical Neuropharmacology · 2025 · Same journal
• The Impact of Age and Severity of Attention Deficit Hyperactivity Disorder (ADHD) Before COVID-19 on the Severity of ADHD During the COVID-19 Lockdowns, as Reported by the Mothers · Clinical Neuropharmacology · 2025 · Same journal
• Electroconvulsive Therapy for Refractory Anxiety and Depression in Superficial Siderosis: A Case Report · Clinical Neuropharmacology · 2025 · Same journal
• Which is More Important to Enhance or Deteriorate Cognitive Functions in Older Adults With Major Cognitive Impairment: The Drug Burden Index or the Total Number of Medications? · Clinical Neuropharmacology · 2025 · Same journal
• Sulforaphane Adjunct to Methylphenidate for Attention-deficit/Hyperactivity Disorder: A Randomized, Double-blind, Placebo-controlled Trial · Clinical Neuropharmacology · 2025 · Same journal